These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

676 related items for PubMed ID: 25577300

  • 1. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, Mi M.
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [Abstract] [Full Text] [Related]

  • 2. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F, Adibi P, Hekmatdoost A.
    Br J Nutr; 2015 Sep 14; 114(5):796-803. PubMed ID: 26234526
    [Abstract] [Full Text] [Related]

  • 3. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.
    Chen S, Zhao X, Wan J, Ran L, Qin Y, Wang X, Gao Y, Shu F, Zhang Y, Liu P, Zhang Q, Zhu J, Mi M.
    Pharmacol Res; 2015 Sep 14; 99():74-81. PubMed ID: 26032587
    [Abstract] [Full Text] [Related]

  • 4. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K, Sattar N, García-Pérez LE, Pavo I, Yu M, Robertson KE, Karanikas CA, Haupt A.
    Diabet Med; 2018 Oct 14; 35(10):1434-1439. PubMed ID: 29869810
    [Abstract] [Full Text] [Related]

  • 5. Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial.
    Qin Y, Zhou Y, Chen SH, Zhao XL, Ran L, Zeng XL, Wu Y, Chen JL, Kang C, Shu FR, Zhang QY, Mi MT.
    PLoS One; 2015 Oct 14; 10(7):e0133496. PubMed ID: 26226139
    [Abstract] [Full Text] [Related]

  • 6. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A.
    Nutr Res; 2014 Oct 14; 34(10):837-43. PubMed ID: 25311610
    [Abstract] [Full Text] [Related]

  • 7. Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32].
    Rotman Y.
    Dig Liver Dis; 2015 Dec 14; 47(12):1090. PubMed ID: 26382727
    [No Abstract] [Full Text] [Related]

  • 8. Authors' reply to the comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32].
    Zhu JD, Zhang QY, Mi MT.
    Dig Liver Dis; 2015 Dec 14; 47(12):1090-1. PubMed ID: 26364558
    [No Abstract] [Full Text] [Related]

  • 9. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.
    Askari F, Rashidkhani B, Hekmatdoost A.
    Nutr Res; 2014 Feb 14; 34(2):143-8. PubMed ID: 24461315
    [Abstract] [Full Text] [Related]

  • 10. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
    Wicklow B, Wittmeier K, T' Jong GW, McGavock J, Robert M, Duhamel T, Dolinsky VW.
    Biochem Cell Biol; 2015 Oct 14; 93(5):522-30. PubMed ID: 26305052
    [Abstract] [Full Text] [Related]

  • 11. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Mirhafez SR, Farimani AR, Dehhabe M, Bidkhori M, Hariri M, Ghouchani BF, Abdollahi F.
    J Gastrointestin Liver Dis; 2019 Jun 01; 28():183-189. PubMed ID: 31204416
    [Abstract] [Full Text] [Related]

  • 12. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G.
    BMC Complement Altern Med; 2019 Mar 12; 19(1):59. PubMed ID: 30871514
    [Abstract] [Full Text] [Related]

  • 13. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ.
    Clin Gastroenterol Hepatol; 2014 Dec 12; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease].
    Wang W, Shi LP, Shi L, Xu L.
    Zhonghua Nei Ke Za Zhi; 2018 Feb 01; 57(2):101-106. PubMed ID: 29397594
    [Abstract] [Full Text] [Related]

  • 15. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease.
    Jegatheesan P, Beutheu S, Ventura G, Sarfati G, Nubret E, Kapel N, Waligora-Dupriet AJ, Bergheim I, Cynober L, De-Bandt JP.
    Clin Nutr; 2016 Feb 01; 35(1):175-182. PubMed ID: 25736031
    [Abstract] [Full Text] [Related]

  • 16. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
    Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bønløkke Pedersen S, Grønbæk H.
    Scand J Gastroenterol; 2016 Feb 01; 51(4):456-64. PubMed ID: 26784973
    [Abstract] [Full Text] [Related]

  • 17. Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial.
    Lorvand Amiri H, Agah S, Mousavi SN, Hosseini AF, Shidfar F.
    Arch Iran Med; 2016 Sep 01; 19(9):631-8. PubMed ID: 27631178
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.
    Abd El-Kader SM, Al-Shreef FM, Al-Jiffri OH.
    Afr Health Sci; 2016 Mar 01; 16(1):242-9. PubMed ID: 27358638
    [Abstract] [Full Text] [Related]

  • 20. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, Mazur A, Neuhoff-Murawska J, Matusik P, Socha P.
    J Pediatr; 2015 Jun 01; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.